Adenovirus Infection Management

Supportive Care and Infection Control

• The American Academy of Ophthalmology and other medical societies recommend providing symptomatic relief with artificial tears for conjunctivitis, cold compresses, and oral analgesics for pain management in patients with adenovirus infection 1
• The Centers for Disease Control and Prevention (CDC) advise maintaining adequate hydration, particularly in patients with gastrointestinal manifestations of adenovirus infection 2
• The CDC also recommend monitoring for secondary bacterial infections, but avoiding prophylactic antibiotics as they provide no benefit for viral infections and may cause unnecessary toxicity 1, 3
• The CDC suggest educating patients about the highly contagious nature of adenovirus, which can survive for weeks on surfaces, and advising minimizing contact with others for 10-14 days from symptom onset 1, 2
• The CDC recommend implementing standard, contact, and droplet precautions in healthcare settings, including hand hygiene with soap and water or alcohol-based hand rubs 4, 5
• The CDC advise wearing gloves when entering the room of patients with confirmed or suspected adenovirus infection, and wearing gowns when soiling with respiratory secretions is anticipated 4, 5
• The CDC suggest wearing a surgical mask and eye protection or face shield when within 3 feet of a patient with suspected or confirmed adenovirus infection 4, 5
• The CDC recommend placing patients in private rooms when possible or cohorting with other adenovirus-infected patients without other infections 4, 5, 6
• The CDC advise disinfecting surfaces with EPA-registered hospital disinfectants or sodium hypochlorite (1:10 dilution of household bleach) 1, 3

Special Considerations

• The American Academy of Ophthalmology recommends considering topical corticosteroids (fluorometholone, rimexolone, or loteprednol) with mandatory close ophthalmology follow-up for severe adenoviral keratoconjunctivitis with subepithelial infiltrates causing blurred vision or photophobia 1, 3
• The American Academy of Ophthalmology advises monitoring for increased intraocular pressure and cataract formation when using corticosteroids 1, 3
• The American Academy of Ophthalmology suggests tapering slowly to the minimum effective dose, recognizing that corticosteroids may prolong viral shedding 1
• The American Academy of Ophthalmology recommends debriding membranes in membranous conjunctivitis to prevent corneal epithelial abrasions or permanent cicatricial changes 1

Antiviral Therapy

• The European Society for Medical Oncology recommends cidofovir as the drug of choice for severely ill immunocompromised patients with adenovirus-associated disease (pneumonia, hepatitis, disseminated infection, or severe gastroenteritis) 7
• The European Society for Medical Oncology advises considering low-dose cidofovir (1 mg/kg three times weekly) or standard dosing (5 mg/kg once weekly for 2 weeks, then once every other week) based on severity and renal function 7
• The European Society for Medical Oncology recommends monitoring closely for nephrotoxicity, which is the primary limiting adverse effect of cidofovir 7

Diagnostic Approach

• The CDC recommend promptly performing rapid diagnostic laboratory tests (sensitivity 88-89%, specificity 91-94%) or PCR testing on patients admitted with symptoms to facilitate early initiation of treatment when indicated 5, 6, 2
• The CDC advise using nasopharyngeal swabs for respiratory disease and conjunctival swabs for ocular disease 2

Common Pitfalls to Avoid

• The CDC recommend not prescribing antibiotics for adenovirus infection in immunocompetent patients, as they provide no benefit and contribute to antimicrobial resistance 1, 3
• The American Academy of Ophthalmology advises not using topical corticosteroids for conjunctivitis without confirming the diagnosis is not herpes simplex virus, as corticosteroids can worsen HSV infections and lead to corneal scarring 1, 3
• The CDC suggest not underestimating the contagiousness of adenovirus—the virus survives for weeks on surfaces, requiring rigorous infection control measures 1, 2
• The European Society for Medical Oncology recommends not all immunocompromised patients require antiviral treatment—reserve cidofovir for severe or disseminated disease given its nephrotoxicity 7
• The CDC advise restricting healthcare personnel with acute upper respiratory tract infections from caring for high-risk patients (infants, immunocompromised, cardiac patients, premature infants) 4, 6